Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 536-543

  Zeng, Rui Xiang ^b   Li, Xiao Lin ^a   Zhang, Min Zhou ^b   Guo, Yuan Lin ^a   Zhu, Cheng Gang ^a   Guo, Li Heng ^b   Li, Sha ^a   Zhang, Yan ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

LDL cholesterol; Non HDL cholesterol; Percutaneous coronary intervention; Periprocedural myocardial injury; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE MB; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE INJURY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INJURY; PROSPECTIVE STUDY;

EID: 84908498062     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.030     Document Type: Article

References (35)

1. Prasad A. Slow but steady progress towards understanding peri-procedural myocardial infarction. Eur. Heart J. 2013, 34:1615-1617.
2. Ioannidis J.P., Karvouni E., Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J.Am. Coll. Cardiol. 2003, 42:1406-1411.
3. Prasad A., Singh M., Lerman A., et al. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J.Am. Coll. Cardiol. 2006, 48:1765-1770.
4. Prasad A., Rihal C.S., Lennon R.J., et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ. Cardiovasc. Interv. 2008, 1:10-19.
5. Feldman D.N., Kim L., Rene A.G., et al. Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter. Cardiovasc. Interv. 2011, 77:1020-1030.
6. Mangiacapra F., Patti G., Peace A., et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am. J. Cardiol. 2010, 106:619-623.
7. Park K.W., Jeon K.H., Kang S.H., et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am. J. Cardiol. 2011, 108:1556-1563.
8. Garg A., Grundy S.M. Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153-169.
9. National Cholesterol Education Program Expert Panel on Detection, E and Treatment of High Blood Cholesterol in, A Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
10. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
11. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005, 112:3375-3383.
12. Cui Y., Blumenthal R.S., Flaws J.A., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 2001, 161:1413-1419.
13. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26:16-23.
14. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel, m An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia - full report. J.Clin. Lipidol. 2014, 8:29-60.
15. Li X.L., Li J.J., Guo Y.L., et al. Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. J.Clin. Lipidol. 2014, 8:423-432.
16. American Diabetes, A Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl.1):S5-S13.
17. Ryden L., Grant P.J., Anker S.D., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2014, 35:1824.
18. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Eur. Heart J. 2007, 28:2525-2538.
19. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. J.Am. Coll. Cardiol. 2012, 60:1581-1598.
20. Sattler K.J., Herrmann J., Yun S., et al. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur. Heart J. 2009, 30:1894-1902.
21. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J.Am. Coll. Cardiol. 1998, 32:584-589.
22. Mathew V., Gersh B.J., Williams B.A., et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004, 109:476-480.
23. De Luca G., Gibson C.M., Bellandi F., et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009, 207:181-185.
24. Robertson B.J., Gascho J.A., Gabbay R.A., et al. Usefulness of hyperglycemia in predicting renal and myocardial injury in patients with diabetes mellitus undergoing percutaneous coronary intervention. Am. J. Cardiol. 2004, 94:1027-1029.
25. Reaven G.M. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987, 36:1-8.
26. Barrett-Connor E., Grundy S.M., Holdbrook M.J. Plasma lipids and diabetes mellitus in an adult community. Am. J. Epidemiol. 1982, 115:657-663.
27. Niskanen L., Turpeinen A., Penttila I., et al. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998, 21:1861-1869.
28. Haffner S.M., American Diabetes, A Management of dyslipidemia in adults with diabetes. Diabetes Care 2003, 26(Suppl.1):S83-S86.
29. Vosper H., Khoudoli G.A., Graham T.L., et al. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol. Ther. 2002, 95:47-62.
30. Herz M., Johns D., Reviriego J., et al. Arandomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther. 2003, 25:1074-1095.
31. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. J.Am. Med. Assoc. 2005, 294:326-333.
32. Liu J., Sempos C.T., Donahue R.P., et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am. J. Cardiol. 2006, 98:1363-1368.
33. Holme I., Aastveit A.H., Jungner I., et al. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J.Intern. Med. 2008, 264:30-38.
34. Robinson J.G., Wang S., Smith B.J., et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J.Am. Coll. Cardiol. 2009, 53:316-322.
35. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am. J. Cardiol. 1998, 81:26B-31B.